Executive Summary Bispecific antibodies (BsAbs) are transforming the landscape of solid tumour treatment. With over 574 active clinical trials and several regulatory approvals, BsAbs are gaining rapid momentum. This Rugia BioIntel Brief explores key mechanisms, target combinations, funding patterns, and competitive insights. Scientific Context BsAbs are engineered to bind two distinct targets, enabling novel mechanisms of tumor targeting, immune cell recruitment, and dual che